the main focus of genelux is oncolytic immunotherapy based on attenuated genetically engineered oncolytic viruses as therapeutic agent in 2013 genelux obtained the san diego business journal innovation award in the category of medical research genelux corp is headquartered in san diego california with a business office in redlands california genelux s lead oncology compound is gl onc1 clinical grade formulation of the laboratory strain glv 1h68 an oncolytic vaccinia virus in november 2013 gl onc1 has been selected as one of the top 10 oncology projects to watch by elsevier business intelligence currently gl onc1 is being evaluated in human clinical phase i ii studies including an ongoing phase ii trial in recurrent ovarian cancer in those studies gl onc1 was shown to be well tolerated and evidence of tumor colonization and indications for therapeutic efficacy were observed in addition to gl onc1 genelux sponsors a veterinary trial in dogs with cancer that is conducted at the cvs angel care cancer center in carlsbad california the dogs are treated with v vet1 a non genetically modified vaccinia virus isolate laboratory name livp6 1 1 with an inactive thymidine kinase gene the preclinical pipeline of genelux includes numerous genetically modified